A decade ago, the global community established the goal to end AIDS as a public health threat by 2030 through reducing new HIV infections and AIDS-related deaths by 90% from 2010 levels.1 Progress has ...

Lenacapavir, new twice-yearly HIV injection, raises hope for pill-weary patients. Discordant couples, sex workers hail ‘game ...

An investigational once-weekly oral antiretroviral therapy (ART) combination effectively maintained viral suppression in ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The World Health Organization has suggested global release of lenacapavir, a twice-yearly injectable medication, as a powerful HIV infection-fighting medication. The historic suggestion was made ...

Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.In a statement, Health ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...

: WHO-approved HIV preventive drug Lenacapavir to be rolled out next year to allow for changes in existing guidelines and ...

Kenya is among nine African countries selected to introduce Lenacapavir, a groundbreaking long-acting injectable HIV ...

GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...